TY - JOUR
T1 - Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer
T2 - Review of the ACCENT collaborative group
AU - Gill, Sharlene
AU - Sargent, Daniel J.
PY - 2008/7
Y1 - 2008/7
N2 - The Adjuvant Colon Cancer Endpoints (ACCENT) Group is an international, collaborative, individual-patient data analysis now including 20,898 patients enrolled in 18 adjuvant therapy trials for resected stage II and stage III colon cancer, spanning the years 1977 to 1999. This article discusses the proceedings published and presented since the inception of the ACCENT Group in 2003, which notably include the evaluation of 3-year disease-free survival as an acceptable end point in adjuvant studies, particularly in stage III colon cancer, and an improved understanding of the time-dependent patterns of failure and benefi t of adjuvant therapy.
AB - The Adjuvant Colon Cancer Endpoints (ACCENT) Group is an international, collaborative, individual-patient data analysis now including 20,898 patients enrolled in 18 adjuvant therapy trials for resected stage II and stage III colon cancer, spanning the years 1977 to 1999. This article discusses the proceedings published and presented since the inception of the ACCENT Group in 2003, which notably include the evaluation of 3-year disease-free survival as an acceptable end point in adjuvant studies, particularly in stage III colon cancer, and an improved understanding of the time-dependent patterns of failure and benefi t of adjuvant therapy.
UR - http://www.scopus.com/inward/record.url?scp=84857429522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857429522&partnerID=8YFLogxK
U2 - 10.1007/s11888-008-0025-y
DO - 10.1007/s11888-008-0025-y
M3 - Review article
AN - SCOPUS:84857429522
SN - 1556-3790
VL - 4
SP - 155
EP - 159
JO - Current Colorectal Cancer Reports
JF - Current Colorectal Cancer Reports
IS - 3
ER -